Indeed, Sobo-Vujanovic et al. and our own work demonstrated that sTNFα blockade prevents chemical induced skin carcinogenesis and overcomes trastuzumab resistance in HER2-positive breast cancer models, respectively (71, 151). Here, ERBB2 is linked to breast carcinoma.